Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

Part of paid clinical trials in Brooklyn, New York.

Sponsor
Narrows Institute for Biomedical Research
Study ID
NCT06952517
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Papular-pustular Rosacea
  • Papulopustular Rosacea
  • Papulopustular Rosacea (PPR)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Clascoterone Cream 1% — DRUG
    Clascoterone 1% cream

Study Details

To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.

Key Dates

Start date
Mar 14, 2025
Status verified
Apr 2025
Primary completion
Sep 1, 2025
Completion
Sep 30, 2025

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Patients with Acneiform or Papulopustular Rosacea
    Patients with diagnosis of papulopustular or acneiform rosacea

Primary Outcome Measure

Biopsy proven reduction in size of sebaceous glands at the end of 12 weeks of treatment compared to the baseline. [ Time Frame: From enrollment to end of treatment at 12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
New York Harbor VA Brooklyn CampusBrooklynNew York11209
Kayla Zafar, BA
[email protected]
718-836-6600
Jared Jagdeo, MD MS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Brooklyn, NY

By research site
New York Harbor VA Brooklyn Campus· Brooklyn, NY